Literature DB >> 18172443

B cells flying solo.

Joanna Groom1, Fabienne Mackay.   

Abstract

Systemic autoimmunity such as systemic lupus erythematosus (SLE) is associated with the loss of B-cell tolerance, B-cell dysregulation and autoantibody production. While some autoantibodies may contribute to the pathology seen with SLE, numerous studies have shown that dysregulation of T-cell function is another critical aspect driving disease. The positive results obtained in clinical trials using T-cell- or B-cell-specific treatments have suggested that cooperation between T and B cells probably underlies disease progression in many patients. A similar cooperative mechanism seemed to explain SLE developing in mice overexpressing the B-cell-activating factor from the tumor necrosis factor family (BAFF). However, surprisingly, T-cell-deficient BAFF transgenic (Tg) mice develop SLE similar to T-cell-sufficient BAFF Tg mice, and the disease was linked to innate activation of B cells and production of proinflammatory autoantibody isotypes. In conclusion, dysregulated innate activation of B cells alone can drive disease independently of T cells, and as such this aspect represents a new pathogenic mechanism in autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172443     DOI: 10.1038/sj.icb.7100142

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  11 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 2.  Autoimmunity at the ocular surface: pathogenesis and regulation.

Authors:  M E Stern; C S Schaumburg; R Dana; M Calonge; J Y Niederkorn; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2010-05-19       Impact factor: 7.313

3.  Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease.

Authors:  Michael E Stern; Chris S Schaumburg; Karyn F Siemasko; Jianping Gao; Larry A Wheeler; Devin A Grupe; Cintia S De Paiva; Virginia L Calder; Margarita Calonge; Jerry Y Niederkorn; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-24       Impact factor: 4.799

4.  A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.

Authors:  Smadar Lapter; Hava Ben-David; Amir Sharabi; Heidy Zinger; Alona Telerman; Maya Gordin; Lin Leng; Richard Bucala; Idit Shachar; Edna Mozes
Journal:  Immunology       Date:  2010-08-25       Impact factor: 7.397

Review 5.  Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease.

Authors:  Reiko M Onishi; Sarah L Gaffen
Journal:  Immunology       Date:  2010-03       Impact factor: 7.397

Review 6.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

7.  Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Authors:  Agnès Doreau; Alexandre Belot; Jérémy Bastid; Benjamin Riche; Marie-Claude Trescol-Biemont; Bruno Ranchin; Nicole Fabien; Pierre Cochat; Claire Pouteil-Noble; Pierre Trolliet; Isabelle Durieu; Jacques Tebib; Berhouz Kassai; Stéphane Ansieau; Alain Puisieux; Jean-François Eliaou; Nathalie Bonnefoy-Bérard
Journal:  Nat Immunol       Date:  2009-05-31       Impact factor: 25.606

Review 8.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Authors:  Michael P Cancro; David P D'Cruz; Munther A Khamashta
Journal:  J Clin Invest       Date:  2009-05-01       Impact factor: 14.808

9.  BAFF is increased in renal transplant patients following treatment with alemtuzumab.

Authors:  D Bloom; Z Chang; K Pauly; J Kwun; J Fechner; C Hayes; M Samaniego; S Knechtle
Journal:  Am J Transplant       Date:  2009-06-12       Impact factor: 8.086

10.  Autoimmune retinopathy in systemic lupus erythematosus: histopathologic features.

Authors:  Xiaoguang Cao; Rachel J Bishop; Farzin Forooghian; Youngeun Cho; Robert N Fariss; Chi-Chao Chan
Journal:  Open Ophthalmol J       Date:  2009-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.